DNA ploidy measurement in oral leukoplakia: Different results between flow and image cytometry

• Published in: Oral oncology Vol. 48; no. 7; pp. 636 - 640
• Main Authors: Brouns, E.R.E.A, Bloemena, E, Belien, J.A.M, Broeckaert, M.A.M, Aartman, I.H.A, van der Waal, I
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.07.2012; Elsevier
• Subjects: Adult; Age; Aged; Aneuploidy; Biological and medical sciences; Diploids; DNA; DNA ploidy; DNA, Neoplasm - genetics; Dysplasia; Facial bones, jaws, teeth, parodontium: diseases, semeiology; Female; Flow cytometry; Flow Cytometry - methods; Hematology, Oncology and Palliative Medicine; Humans; Image cytometry; Image Cytometry - methods; Leukokeratosis; Leukoplakia, Oral - genetics; Male; Medical sciences; Middle Aged; Non tumoral diseases; Oral epithelial dysplasia; Oral leukoplakia; Oral squamous cell carcinoma; Otolaryngology; Otorhinolaryngology. Stomatology; Ploidy; Potentially malignant disorder; Reproducibility of Results; Retrospective Studies; Risk groups; Statistical analysis; Transformation; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology; DNA ploidy; Flow cytometry; Oral epithelial dysplasia; Potentially malignant disorder; Image cytometry; Oral leukoplakia; Oral squamous cell carcinoma; Measurement; Dysplasia; Ploidy; Premalignant lesion; Stomatology; Oral administration; ENT; Malignant tumor; Cancerology; DNA; Oral cavity disease; Oral leukoplasia; Oral premalignant lesion; Cancer
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/j.oraloncology.2012.01.013

Summary The estimated prevalence of oral leukoplakia is worldwide approximately 2%, with an annual malignant transformation rate of approximately 1%. The aim of the present study was to evaluate the possible contribution of ploidy measurement to the prediction of the clinical course, in a well defined cohort of patients with oral leukoplakia. Ploidy was measured by both flow cytometry (FCM-DNA) and image cytometry (ICM-DNA) and we focussed on the comparison of the two different techniques to determine ploidy. A total of 41 patients have been included, with a mean age of 59 years (range 36–78 years). With FCM-DNA, three lesions were aneuploid, with ICM-DNA, 19 lesions were aneuploid. DNA ploidy was compared with clinicopathological and patients parameters. There were no statistically significant differences between DNA ploidy and any patient factor with both FCM-DNA and ICM-DNA. Using FCM-DNA, DNA aneuploid lesions showed statistically significant more dysplasia ( p = 0.04) than diploid lesions. Furthermore, DNA aneuploid lesions were more frequently encountered at high-risk locations ( p = 0.03) as being determined with FCM-DNA. These relations were not found when DNA ploidy was determined with ICM-DNA.